Point72 Asia Singapore Pte. Ltd. Sells 3,902 Shares of Humana Inc. (NYSE:HUM)

Point72 Asia Singapore Pte. Ltd. trimmed its position in Humana Inc. (NYSE:HUM) by 86.9% in the second quarter, Holdings Channel reports. The fund owned 587 shares of the insurance provider’s stock after selling 3,902 shares during the quarter. Point72 Asia Singapore Pte. Ltd.’s holdings in Humana were worth $219,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Cambridge Investment Research Advisors Inc. boosted its stake in shares of Humana by 12.3% during the fourth quarter. Cambridge Investment Research Advisors Inc. now owns 10,323 shares of the insurance provider’s stock valued at $4,726,000 after purchasing an additional 1,127 shares in the last quarter. Parallel Advisors LLC increased its position in Humana by 8.9% in the 4th quarter. Parallel Advisors LLC now owns 1,980 shares of the insurance provider’s stock valued at $906,000 after acquiring an additional 161 shares during the period. Edmond DE Rothschild Holding S.A. raised its stake in shares of Humana by 1,168.0% during the fourth quarter. Edmond DE Rothschild Holding S.A. now owns 317 shares of the insurance provider’s stock valued at $145,000 after acquiring an additional 292 shares during the last quarter. Steward Partners Investment Advisory LLC lifted its holdings in shares of Humana by 14.1% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,527 shares of the insurance provider’s stock worth $2,072,000 after purchasing an additional 558 shares during the period. Finally, Stifel Financial Corp grew its stake in shares of Humana by 3.0% in the fourth quarter. Stifel Financial Corp now owns 51,433 shares of the insurance provider’s stock worth $23,547,000 after purchasing an additional 1,504 shares during the last quarter. Institutional investors and hedge funds own 92.38% of the company’s stock.

Humana Trading Up 0.3 %

HUM opened at $313.04 on Friday. The firm has a market capitalization of $37.72 billion, a PE ratio of 19.49, a P/E/G ratio of 2.44 and a beta of 0.50. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.66 and a quick ratio of 1.66. Humana Inc. has a fifty-two week low of $298.61 and a fifty-two week high of $530.54. The company’s 50-day moving average is $352.81 and its 200 day moving average is $344.87.

Humana (NYSE:HUM) last posted its earnings results on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share for the quarter, beating analysts’ consensus estimates of $5.89 by $1.07. Humana had a return on equity of 16.12% and a net margin of 1.53%. The company had revenue of $29.54 billion for the quarter, compared to analyst estimates of $28.52 billion. During the same quarter last year, the company earned $8.94 earnings per share. The company’s revenue for the quarter was up 10.4% on a year-over-year basis. As a group, research analysts predict that Humana Inc. will post 16.01 earnings per share for the current fiscal year.

Humana Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Monday, September 30th will be issued a $0.885 dividend. The ex-dividend date is Monday, September 30th. This represents a $3.54 annualized dividend and a dividend yield of 1.13%. Humana’s dividend payout ratio is currently 22.04%.

Analyst Upgrades and Downgrades

Several research analysts have commented on the company. Baird R W raised Humana to a “hold” rating in a report on Thursday, May 30th. Robert W. Baird assumed coverage on shares of Humana in a research report on Thursday, May 30th. They set a “neutral” rating and a $374.00 target price for the company. JPMorgan Chase & Co. boosted their target price on shares of Humana from $332.00 to $396.00 and gave the company a “neutral” rating in a report on Wednesday, August 21st. Deutsche Bank Aktiengesellschaft lifted their price objective on Humana from $341.00 to $349.00 and gave the stock a “hold” rating in a research report on Friday, August 2nd. Finally, Oppenheimer upped their target price on Humana from $370.00 to $400.00 and gave the company an “outperform” rating in a research report on Thursday, August 1st. Thirteen equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $398.70.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.